“On behalf of all the people who are part of Gilead, we are proud to be here collecting this award that recognizes a key aspect of what the company’s work is.”. These are the words of María Río, vice president and general director of Gilead Spain, who received the Fundamed Award in the R + D + i category this Tuesday.
Rio stressed that “Gilead has made research its hallmark”. “We have contributed to the transformation of diseases such as HIV or hepatitis C and now we are hopeful with the role of cell therapies,” he stressed.
In addition, the general director stressed that they have had “the opportunity to fight against COVID-19 by developing the antiviral that has been the first approved treatment.” In the same line, Rio recalled that Spain is the second country, after the US, where there are more resources involved in research, as has happened with remdesivir.
–
The company spokeswoman reviewed initiatives to promote research with scholarship programs, such as the one carried out in collaboration with the Carlos III Health Institute, of which they are very satisfied. “Being recognized as innovators makes us especially proud,” he concluded.
A great tour
An unwavering commitment to R&D and determination to make the impossible possible are the pillars on which Gilead has built its strategy to transform the areas where it is present: advanced therapies CAR-T, HIV, hepatitis C and SARS-CoV-2, developing treatments with which to improve the quality of life of patients given its commitment to the health of citizens.
In times of pandemic, your drug remdesivir It was the first broad-spectrum antiviral licensed in more than 50 regions and countries around the world, including the European Union and the United States, for the treatment of COVID-19 in patients with pneumonia who require supplemental oxygen.
“That we are recognized as innovators makes us feel very proud,” said María Río
Despite the difficulties, Gilead has continued to encourage the development of its pipeline in areas with unmet needs, strengthening its position in liver disease and oncology.
In this field, all eyes are on the development of sacituzumab govitecan-hziy, a conjugated antibody drug, which specialists call ‘Trojan horses’, with great expectations in breast cancer and urothelial cancer.
In cell therapy, Gilead has made significant progress in 2020. With Yescarta® and Tecartus® on the market, it will be the first biopharmaceutical company with two commercial CAR-T approved in the EU.
You can access all the information on candidatures and finalists here:
–
